All types of drugs are expected to be affected to lesser or greater degrees by the COVID-19 outbreak in South Korea in 2020. Antiviral and respiratory drugs, along with those used for treating life-threatening conditions are expected to be the least affected. In contrast, drugs for non-urgent illnesses and conditions are expected to be most affected, as people stay away from hospitals if possible.
Adjusted pharmaceutical sales forecast in South Korea in 2020, by drug type (in billion South Korean won)
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Coronavirus: the pharma and medtech response
Pharma - before the pandemic
6
- Premium Statistic Pharmaceutical market: worldwide revenue 2001-2023
- Premium Statistic Top global pharmaceutical companies based on pharma revenue 2022
- Premium Statistic Size of the global vaccine market by region 2014-2024
- Premium Statistic Leading pharmaceutical companies by global vaccine revenue 2021
- Basic Statistic Global anti-viral market size 2019 and 2027 forecast
- Premium Statistic Leading pharmaceutical companies by global anti-viral revenue 2017 and 2024
Treatments and vaccines
8
- Basic Statistic Biotechs: duration of COVID-19 response compared to previous health threats 2003-2019
- Premium Statistic Number of registered COVID-19 studies worldwide Apr 2020 - Dec 2022, by region
- Basic Statistic Number of COVID-19 drugs in development worldwide by phase June 2022
- Premium Statistic Top companies by COVID-19 treatment vaccines in development June 2022
- Basic Statistic Number of COVID-19 treatment vaccine trials worldwide by phase June 2022
- Basic Statistic Number of COVID-19 treatment vaccine trials worldwide by type June 2022
- Premium Statistic Select COVID-19 vaccine pricing and funding as of August 2020
- Basic Statistic Gilead Science's remdesivir manufacturing projections 2020
Focus: BioNTech and Moderna
7
- Basic Statistic COVID-19 vaccine comparison Biontech/Pfizer vs Moderna 2020
- Basic Statistic Revenue of BioNTech 2017-2023
- Basic Statistic Operating income of BioNTech 2017-2023
- Basic Statistic Total assets of BioNTech 2017-2023
- Basic Statistic Moderna's revenue 2016-2023
- Basic Statistic R&D expenses of Moderna 2016-2023
- Basic Statistic R&D expenses of Moderna by type 2023
Opinions on COVID-19 vaccines
6
- Basic Statistic U.S. adults who would get a coronavirus vaccine, Jan. 2020 to Jan. 2021
- Basic Statistic U.S. adults who would hypothetically get a coronavirus vaccine as of 2020, by gender
- Basic Statistic U.S. adults who would hypothetically get a coronavirus vaccine October 2020, by age
- Basic Statistic Share of Canadians who would get vaccinated for COVID Jul. 2020 - Mar. 2021
- Premium Statistic Willingness to wait before getting COVID-19 vaccine once available in Italy 2020
- Basic Statistic Brazil: intention to get immunized against COVID-19 2021
Business impact
4
- Basic Statistic Market capitalization change in key COVID-19 firms until end-May 2020
- Basic Statistic Top challenges for pharmaceutical companies during COVID-19 2020
- Basic Statistic Launch disruption on global pharmaceutical market due to coronavirus 2020-2025
- Premium Statistic Covid-19 impact: global pharma specialty excipient demand CAGR 2019-2024
Medtech - before the pandemic
5
- Premium Statistic Total medtech revenue worldwide 2011-2024
- Premium Statistic In-vitro diagnostics market revenue worldwide 2016-2028
- Premium Statistic Global in vitro diagnostics market share by top medtech companies 2017 and 2024
- Basic Statistic Global ventilator market size 2018-2026
- Premium Statistic Global ventilator market size by type 2018-2026
Ventilators and testing
7
- Basic Statistic Number of COVID-19-related EUAs for ventilators developed by company May 2020
- Basic Statistic Respiratory devices with potential being modified to ventilators by company 2020
- Basic Statistic Weekly ventilator production change in U.S. due to COVID-19 until April 2020
- Basic Statistic Cumulative EUAs granted to COVID-19 tests March-November 2020
- Basic Statistic Accuracy figures for selected COVID-19 antibody tests sold in the US 2020
- Basic Statistic Number of COVID-19 tests carried out daily in U.S. March-November2020
- Basic Statistic Rate change of COVID-19 testing in select countries April-November 2020
Further related statistics
10
- Celgene's revenue and net income 2006-2018
- Medicinal market growth worldwide including rebates 2009-2018
- Expenditure worldwide on diabetes by market 2013-2018
- Key figures on established biotech centers worldwide 2012-2016
- M&A capacities - changes for the global pharma industry 2008-2015
- AstraZeneca's revenue from top product Pulmicort 2006-2023
- CVS Health's total assets 2005-2023
- Walgreens gross profit and net earnings in the U.S. 2005-2023
- Revenue of Sinopharm 2011-2022, by category
- Number of employees at Sinopharm 2011-2022
Further Content: You might find this interesting as well
Statistics
- Celgene's revenue and net income 2006-2018
- Medicinal market growth worldwide including rebates 2009-2018
- Expenditure worldwide on diabetes by market 2013-2018
- Key figures on established biotech centers worldwide 2012-2016
- M&A capacities - changes for the global pharma industry 2008-2015
- AstraZeneca's revenue from top product Pulmicort 2006-2023
- CVS Health's total assets 2005-2023
- Walgreens gross profit and net earnings in the U.S. 2005-2023
- Revenue of Sinopharm 2011-2022, by category
- Number of employees at Sinopharm 2011-2022
IQVIA. (March 31, 2020). Adjusted pharmaceutical sales forecast in South Korea in 2020, by drug type (in billion South Korean won) [Graph]. In Statista. Retrieved June 10, 2024, from https://www.statista.com/statistics/1120102/south-korea-pharmaceutical-sales-forecast-by-drug-type/
IQVIA. "Adjusted pharmaceutical sales forecast in South Korea in 2020, by drug type (in billion South Korean won)." Chart. March 31, 2020. Statista. Accessed June 10, 2024. https://www.statista.com/statistics/1120102/south-korea-pharmaceutical-sales-forecast-by-drug-type/
IQVIA. (2020). Adjusted pharmaceutical sales forecast in South Korea in 2020, by drug type (in billion South Korean won). Statista. Statista Inc.. Accessed: June 10, 2024. https://www.statista.com/statistics/1120102/south-korea-pharmaceutical-sales-forecast-by-drug-type/
IQVIA. "Adjusted Pharmaceutical Sales Forecast in South Korea in 2020, by Drug Type (in Billion South Korean Won)." Statista, Statista Inc., 31 Mar 2020, https://www.statista.com/statistics/1120102/south-korea-pharmaceutical-sales-forecast-by-drug-type/
IQVIA, Adjusted pharmaceutical sales forecast in South Korea in 2020, by drug type (in billion South Korean won) Statista, https://www.statista.com/statistics/1120102/south-korea-pharmaceutical-sales-forecast-by-drug-type/ (last visited June 10, 2024)
Adjusted pharmaceutical sales forecast in South Korea in 2020, by drug type (in billion South Korean won) [Graph], IQVIA, March 31, 2020. [Online]. Available: https://www.statista.com/statistics/1120102/south-korea-pharmaceutical-sales-forecast-by-drug-type/